Latest Regulatory Filings News

Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.

News Corporation reported a 3% revenue increase to $2.009 billion for Q3 2025, with net income attributable to stockholders tripling to $137 million. The company completed the strategic sale of Foxtel, marking a significant shift in its operations.

Donaco International Limited has postponed its Scheme of Arrangement timetable amid extended legal and valuation reviews, while revealing a new 10% VAT gaming tax liability in Cambodia effective from January 2025.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

Coronado Global Resources Inc. posted a $96.2 million net loss for Q1 2025, reflecting weak metallurgical coal prices and ongoing liquidity challenges. The company is navigating covenant waivers and pursuing refinancing amid market uncertainty.

Catalina Resources has successfully completed its entitlement and shortfall offer, raising over $2.27 million to strengthen its cash position and advance its diverse mineral projects.

NSX Limited has successfully closed a $1.3 million share placement, exceeding its initial $1.1 million target and reinforcing its position as Australia’s second largest exchange.

DMC Mining Limited has extended the closing date for its public share offer to August 2025 due to delays in securing exploration licences for its key Guinea projects. The company plans further regulatory updates to accommodate these changes.

Papyrus Australia has issued a revised Appendix 4C for the March 2025 quarter, correcting the treatment of $527k in R&D expenditure previously reported as cash payments. This adjustment also impacts prior monthly and quarterly cash flow reports dating back to November 2024.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Helia Group’s 1Q25 APRA lodgement reveals robust growth in gross written premiums and statutory net profit, while the company voices concerns over proposed government changes to the Home Guarantee Scheme that could reshape its market dynamics.